FRM
GBT

Fox Run Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Fox Run Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,813
Closed -$239K – 662
2021
Q2 		$239K Buy
+6,813
New +$266K 0.22% 240
2020
Q3 		– Sell
-4,388
Closed -$277K – 358
2020
Q2 		$277K Buy
+4,388
New +$301K 0.37% 132
2019
Q3 		– Sell
-5,515
Closed -$290K – 621
2019
Q2 		$290K Buy
+5,515
New +$317K 0.19% 240

Other funds holding GBT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Fox Run Management's GBT Position: Q3 2021 in Review

Fox Run Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2021, closing a stake of 6,813 shares — an estimated $239K sold.

Fox Run Management first reported a position in GBT in Q2 2019 and held it in 3 quarters. The position peaked at $290K in Q2 2019. 187 funds tracked by Wall St. Rank hold GBT as of Q3 2021.

  • Fox Run Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Fox Run Management sold 6,813 Global Blood Therapeutics, Inc. shares in Q3 2021, an estimated $239K.
  • Fox Run Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2019 and held it in 3 quarters.
  • Fox Run Management's Global Blood Therapeutics, Inc. position peaked at $290K in Q2 2019.
  • 187 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2021.

Based on Fox Run Management's 13F filing for Q3 2021, filed 15 Nov 2021.